> Can’t charge exorbitant fees for something trivial to produce. Read up on escitalopram and esketamine. Both are racemic separations of the original compound

> Can’t charge exorbitant fees for something trivial to produce. Read up on escitalopram and esketamine. Both are racemic separations of the original compound (with anti-depressive properties). Biochemically/medically they're basically identical to the original citalopram and ketamine. Same effect, same side effect. They're literally just the active half of the original compound. But legally a racemic separation which is medically equivalent is still juuuust different enough chemically you can patent it. It seems highly likely to me that a pharma company is going to design and patent a psilocin prodrug with nearly identical effects to mushrooms, that's patentable, and they'll charge tidily for it. (Psilocybin itself in mushrooms is just a prodrug for psilocin.) I suspect if that happens psilocin or psilocybin will never be approved for routine use.